The PMTA Trap: How Regulators Handed Vaping to Big Tobacco

I have been covering vaping since 2011. I watched this industry build itself from scratch — small-batch e-liquid makers working out of garages, hardware modders turning hobby projects into legitimate businesses, a genuine grassroots movement of adults who found something that worked when cigarettes nearly killed them. What the FDA’s regulatory apparatus has done to that industry over the past several years is worth naming plainly, because the people losing the most are not corporations. They are the readers of this publication.

The numbers are stark. As of May 2026, the FDA has authorized approximately 45 electronic nicotine delivery system products for legal sale in the United States. Five brands hold those authorizations: Vuse, NJOY, Logic, JUUL, and Glas. The first four are owned or heavily backed by tobacco industry capital. Glas, a California-based independent company, received its first authorization in March 2025, making it the first independent U.S. vaping brand to successfully navigate the PMTA process — and it did so by building Bluetooth-based age verification directly into the hardware.

Every other vaping product on the market — including the disposables that most American vapers are currently using — has either been denied authorization, never submitted an application, or is operating under a legal gray area while enforcement remains inconsistent. The brands making the devices that most of you reading this prefer right now are, in the strictest regulatory sense, unauthorized.

What a PMTA Actually Costs — and What That Means for Small Brands

The PMTA is not a form. It is a scientific dossier that can run thousands of pages and, according to FDA estimates, cost anywhere from hundreds of thousands to over a million dollars per product. Independent manufacturers who want to bring even a single e-liquid flavor to market legally need to fund toxicological studies, clinical data on use behavior, manufacturing documentation, and evidence that their product is, in the FDA’s language, “appropriate for the protection of public health.”

That last phrase is the one that contains the trap. “Appropriate for the protection of public health” does not mean safe. It means that the FDA must weigh the benefit of the product to adult smokers who might switch against the risk that the product attracts underage users. It is, by design, a balancing test that costs millions of dollars to argue — and one that independent brands with three employees and a production facility cannot afford to make.

When the September 2020 PMTA deadline hit, over one million applications were submitted. The vast majority were refused. The ones that cleared were from companies with legal teams, scientific contractors, and capital reserves that no independent e-liquid maker could match. The consolidation that followed was not a coincidence. It was a predictable outcome of a regulatory structure that functions, in practice, as a barrier to entry that only established players can clear.

Who’s Left Standing — and What That Tells You

Look at the five brands holding FDA authorizations and follow the ownership chains. Vuse is a brand of R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco. NJOY was acquired by Altria — the parent company of Philip Morris USA — in 2023 for $2.75 billion. Logic is owned by Japan Tobacco International. JUUL, despite its regulatory and legal troubles, retains partial Altria investment. Glas is the one genuine outlier, a small independent that succeeded by essentially engineering a compliance solution directly into its hardware.

The pattern is not subtle. The companies that have navigated the PMTA process successfully are either arms of Big Tobacco or have made enormous investments in compliance infrastructure that functionally require tobacco-industry scale to sustain. The independent American e-liquid industry that built the modern vaping market — the one that produced the flavors that actually got people off cigarettes — has been largely regulated out of existence, replaced by the same companies that spent decades lobbying to keep combustible cigarettes on the market.

There is an irony here worth sitting with. The FDA’s stated rationale for the PMTA process is public health. The outcome of that process has been to concentrate market power in the hands of tobacco companies. The industry that posed the most credible competitive threat to combustible cigarettes — small, innovative, flavor-forward independent vaping brands — is the one that absorbed most of the regulatory damage.

The Flavor Restriction Ripple Effect

Flavor is not a minor issue. It is the central issue. The research on why adult smokers switch to vaping consistently points to flavor as one of the primary drivers. Non-tobacco, non-menthol flavors — fruit, dessert, candy, beverage profiles — are what most vapers actually use, and they are the flavors that make the experience different enough from smoking that people do not go back.

The FDA’s position has been that these flavors represent unacceptable youth appeal risk. The result is that all 45 authorized products are tobacco or menthol flavored. No fruit. No dessert. No menthol-fruit combinations. The Glas authorization in May 2026 broke this pattern for the first time, with four fruit-flavored pods cleared for sale — but only because Glas built age-verification technology into the device itself, a solution that requires hardware investment beyond the reach of most independent brands.

Meanwhile, the products most vapers are actually using remain unauthorized and increasingly subject to state-level enforcement action. Multiple states — Virginia, Alabama, Pennsylvania, Tennessee, and others — have established or are establishing vapor product directories that condition retail legality on PMTA authorization status. As those laws take effect, the products most vapers prefer will face removal from shelves not because they were found to be harmful, but because the companies that make them could not afford the regulatory process required to stay legal.

The Advocacy Vacuum — and What Fills It

For fifteen years, the Consumer Advocates for Smoke-free Alternatives Association — CASAA — was the primary consumer voice in U.S. vaping advocacy. It was not an industry organization. It was a 501(c)(4) nonprofit run by volunteers, funded by members, that submitted regulatory comments, organized calls to action, tracked state legislation, and gave individual vapers a structured way to make their voices heard. In August 2025, CASAA ceased its legislative advocacy work due to lack of funding. The website remains online as an educational archive, but the active advocacy engine is gone.

This matters because individual vapers writing to their representatives is not symbolic. It moves policy. Legislators — particularly at the state level — respond to constituent contact in ways that industry lobbying alone cannot replicate. A state legislator who hears from fifty vapers in their district describing how vaping helped them quit smoking is receiving information that no trade association can provide. The CASAA model worked because it made that contact easy and organized. Without it, the burden falls on individual vapers to do the work themselves.

The practical steps are not complicated. Find your federal and state representatives at congress.gov and your state legislature’s website. Write a brief, specific letter — not a form letter — describing your personal experience with vaping as a harm-reduction tool, and your concern about the regulatory pressure threatening your access to the products you use. Be specific about the policy you are writing about. Ask for a response. Do it more than once.

The vaping industry has organizations still working on this — the Vapor Technology Association, Americans for Tax Reform’s tobacco harm reduction work, and several state-level coalitions. None of them have the consumer-facing infrastructure CASAA had, but they are active and worth knowing about.

The Irony Worth Saying Plainly

Combustible cigarettes — the products responsible for approximately 480,000 deaths per year in the United States, according to the CDC — remain freely available at every gas station and convenience store in the country. They require no PMTA. They face no flavor restrictions. Menthol cigarettes, despite years of proposed FDA action, remain on shelves. The regulatory infrastructure that has effectively dismantled independent vaping companies does not apply to the product that vaping was designed to replace.

This is not a conspiracy theory. It is a regulatory outcome. The Tobacco Control Act that gave the FDA authority over tobacco products was co-written with significant input from Philip Morris, which had calculated — correctly, as it turned out — that stringent regulation would entrench existing market share and raise barriers high enough to prevent meaningful competition from new entrants. The PMTA process is functioning exactly as a regulatory capture outcome would predict.

None of this means that vaping regulation is inherently wrong, or that the FDA should have no role in this space. It means that the specific regulatory architecture that was built, and the way it has been applied, has produced outcomes that serve tobacco company interests far better than it serves public health or consumer choice. That is worth saying, clearly, without hedging it into meaninglessness.

What You Can Actually Do

The regulatory wind is shifting slightly. The May 2026 Glas authorizations for fruit-flavored products suggest the FDA is capable of finding paths to flavor authorization when the right compliance mechanisms are in place. RFK Jr.’s public statements about the previous administration’s failures to move American-manufactured products through authorization suggest some political will toward reform. The U.S. Senate has directed $200 million toward enforcement of unauthorized imports, which could — if applied consistently — at least level the playing field between unauthorized domestic brands and the flood of unauthorized imported products.

But none of that changes the structural problem, and none of it happens faster because vapers stay quiet about it. If you are a long-term vaper who switched from smoking, your story is evidence. It is the kind of evidence that the FDA’s public health calculus is supposed to account for and consistently underweights. Legislators and regulators hear from public health advocates constantly. They hear from vapers rarely.

Spinfuel has been covering this industry since 2011. We have watched small brands come and go, watched the market consolidate, watched the advocacy organizations that fought for consumer access struggle to survive. We are still here because this matters — because the adults who found a harm-reduction tool that worked deserve accurate information and a publication willing to say what the regulatory situation actually looks like.

The PMTA maze is still running. The small brands are still disappearing. The tobacco companies are still the ones left standing. And your representative still has a contact form on their website.

Use it.